PE20181619A1 - Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico - Google Patents

Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico

Info

Publication number
PE20181619A1
PE20181619A1 PE2018000728A PE2018000728A PE20181619A1 PE 20181619 A1 PE20181619 A1 PE 20181619A1 PE 2018000728 A PE2018000728 A PE 2018000728A PE 2018000728 A PE2018000728 A PE 2018000728A PE 20181619 A1 PE20181619 A1 PE 20181619A1
Authority
PE
Peru
Prior art keywords
alkyl
therapeutic use
preparation
cryptocygine
novel
Prior art date
Application number
PE2018000728A
Other languages
English (en)
Spanish (es)
Inventor
Antony Bigot
Herve Bouchard
Marie-Priscille Brun
François Clerc
Jidong Zhang
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20181619A1 publication Critical patent/PE20181619A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Bedding Items (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2018000728A 2015-11-05 2016-11-03 Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico PE20181619A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
PE20181619A1 true PE20181619A1 (es) 2018-10-11

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000728A PE20181619A1 (es) 2015-11-05 2016-11-03 Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico

Country Status (36)

Country Link
US (2) US10941139B2 (enExample)
EP (1) EP3371179B1 (enExample)
JP (1) JP6929292B2 (enExample)
KR (1) KR102822076B1 (enExample)
CN (1) CN108349960B (enExample)
AR (1) AR106604A1 (enExample)
AU (1) AU2016347724B2 (enExample)
CA (1) CA3003085A1 (enExample)
CL (1) CL2018001210A1 (enExample)
CO (1) CO2018004581A2 (enExample)
CR (1) CR20180256A (enExample)
CY (1) CY1122441T1 (enExample)
DK (1) DK3371179T3 (enExample)
EA (1) EA035625B1 (enExample)
EC (1) ECSP18034035A (enExample)
ES (1) ES2755101T3 (enExample)
HK (1) HK1256754B (enExample)
HR (1) HRP20191729T1 (enExample)
HU (1) HUE046033T2 (enExample)
IL (1) IL259067B (enExample)
LT (1) LT3371179T (enExample)
MA (1) MA43160B1 (enExample)
MX (1) MX374535B (enExample)
MY (1) MY189448A (enExample)
PE (1) PE20181619A1 (enExample)
PH (1) PH12018500852B1 (enExample)
PL (1) PL3371179T3 (enExample)
PT (1) PT3371179T (enExample)
RS (1) RS59498B1 (enExample)
SG (1) SG11201803181SA (enExample)
SI (1) SI3371179T1 (enExample)
TN (1) TN2018000131A1 (enExample)
TW (1) TWI714661B (enExample)
UY (1) UY36979A (enExample)
WO (1) WO2017076998A1 (enExample)
ZA (1) ZA201802322B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
WO2018206635A1 (en) * 2017-05-10 2018-11-15 Sanofi Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
AU2020231396B2 (en) 2019-03-07 2025-03-20 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
EP4495105A1 (en) 2023-07-17 2025-01-22 Basf Se 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents
EP4495108A1 (en) 2023-07-17 2025-01-22 Basf Se 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203016T1 (de) * 1993-12-21 2001-07-15 Univ Hawaii Cryptophycine
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
AU2016347724A1 (en) 2018-05-10
CO2018004581A2 (es) 2018-07-19
WO2017076998A1 (en) 2017-05-11
ECSP18034035A (es) 2018-05-31
RS59498B1 (sr) 2019-12-31
HUE046033T2 (hu) 2020-01-28
US20190382391A1 (en) 2019-12-19
CY1122441T1 (el) 2021-01-27
PH12018500852B1 (en) 2021-08-11
CN108349960A (zh) 2018-07-31
HRP20191729T1 (hr) 2019-12-13
ES2755101T3 (es) 2020-04-21
EA201890898A1 (ru) 2018-10-31
CN108349960B (zh) 2022-05-27
JP6929292B2 (ja) 2021-09-01
SG11201803181SA (en) 2018-05-30
SI3371179T1 (sl) 2019-11-29
EP3371179A1 (en) 2018-09-12
TWI714661B (zh) 2021-01-01
MX2018005379A (es) 2018-09-05
CL2018001210A1 (es) 2018-08-17
MX374535B (es) 2025-03-06
CR20180256A (es) 2018-08-13
AU2016347724B2 (en) 2021-04-01
MA43160B1 (fr) 2019-12-31
UY36979A (es) 2017-06-30
PH12018500852A1 (en) 2018-10-29
JP2018535255A (ja) 2018-11-29
LT3371179T (lt) 2019-11-11
BR112018008490A2 (pt) 2019-02-12
NZ741734A (en) 2023-10-27
PT3371179T (pt) 2019-11-18
US20210163458A1 (en) 2021-06-03
EP3371179B1 (en) 2019-08-07
IL259067A (en) 2018-06-28
TW201730164A (zh) 2017-09-01
PL3371179T3 (pl) 2020-02-28
KR102822076B1 (ko) 2025-06-18
MY189448A (en) 2022-02-14
CA3003085A1 (en) 2017-05-11
ZA201802322B (en) 2019-01-30
KR20180073678A (ko) 2018-07-02
IL259067B (en) 2021-07-29
US10941139B2 (en) 2021-03-09
TN2018000131A1 (en) 2019-10-04
EA035625B1 (ru) 2020-07-17
DK3371179T3 (da) 2019-11-11
AR106604A1 (es) 2018-01-31
HK1256754B (en) 2020-06-05